Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes.
Download (PDF, 224.9KB) -
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Download (PDF, 126.4KB) -
Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
Download (PDF, 238.3KB) -
Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement.
Download (PDF, 217.4KB) -
Statement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling
GSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.
-
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases
Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
-
New data at ASCO showcases the transformational potential of GSK's oncology portfolio
Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.
Download (PDF, 318.1KB) -
GSK announces positive results from phase III severe asthma trials of depemokimab
Primary endpoints met in SWIFT-1 and SWIFT-2 trials with statistically significant reduction in exacerbations over 52 weeks vs. placebo
Download (PDF, 109.3KB) -
GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)
GSK pledges to support the Fleming Initiative - an innovative and collaborative approach to develop new AMR interventions.
Download (PDF, 146.9KB) -
GSK makes a strong start to 2024 with improving outlook for the year
Q1 2024 performance highlights
Download (PDF, 787.0KB) -
US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial
Download (PDF, 139.4KB) -
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments
GSK has announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin.
Download (PDF, 146.6KB) -
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination.
Download (PDF, 186.1KB) -
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Prescription Drug User Fee Act action date set by FDA for 14 February 2025.
Download (PDF, 201.1KB) -
Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer
Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.
Download (PDF, 207.9KB) -
GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma
Trial unblinded early at an interim analysis based on Independent Data Monitoring Committee recommendation
Download (PDF, 185.7KB) -
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections network at CROI.
Download (PDF, 126.1KB) -
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
GSK announced the company’s first step towards delivering ultra long-acting injectable HIV treatment.
Download (PDF, 136.6KB) -
GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director
GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director.
Download (PDF, 150.6KB) -
Statement: Zantac (ranitidine) litigation
GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord.
Download (PDF, 108.6KB)
